IMR Press / FBL / Volume 16 / Issue 8 / DOI: 10.2741/3891

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article

Detection of EGFR and K-ras mutations for diagnosis of multiple lung adenocarcinomas

Show Less
1 Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
2 Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
3 Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
4 Department of Environmental Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Academic Editor:Norio Kagawa
Front. Biosci. (Landmark Ed) 2011, 16(8), 2961–2969; https://doi.org/10.2741/3891
Published: 1 June 2011
(This article belongs to the Special Issue Gene regulation and structure-function of P450 Cold stress response)
Abstract

The incidence of multiple primary lung adenocarcinoma (MPLA) is increasing, and it is important to distinguish MPLA from intrapulmonary metastasis (IPM) in order to determine the therapeutic strategy. However, there is no reliable method to differentiate between the two. The purpose of this study was to distinguish MPLA from IPM based on the gene status of EGFR and K-ras and the morphological Noguchi classification system. Sixty-eight tumors from 34 cases of clinical MPLA were evaluated. Of them, 11 cases (32.4%) were diagnosed as biological MPLA (bMPLA) by EGFR/K-ras mutation analyses, and 12 cases (35.3%) by morphological analysis. In all, 23 of the 34 cases (67.6%) were diagnosed as bMPLA. The remaining 11 cases were diagnosed as biological IPM (bIPM). The 5-year survival rates of bMPLA and bIPM were 90.9% and 63.6%, respectively (p=0.04). These findings suggest that the combination method including gene mutation and morphological analysis can guide treatment decisions and that there is a need for systemic chemotherapy, and surveillance monitoring.

Share
Back to top